☆ 4.7 Article

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

UniProt: the Universal Protein Knowledgebase in 2023

Alex Bateman et al.

Summary: The UniProt Knowledgebase aims to provide comprehensive, high-quality, and freely accessible protein sequences annotated with functional information. The database has expanded its data processing pipeline and website to accommodate the increasing information content, with over 227 million sequences and plans to include a reference proteome for each taxonomic group. Detailed annotations are extracted from the literature to update or create reviewed entries, while unreviewed entries are supplemented with annotations from automated systems. The new website, https://www.uniprot.org/, offers enhanced user experience and easy access to data, including AlphaFold structures and improved protein subcellular localization visualizations.

NUCLEIC ACIDS RESEARCH (2023)

添加到收藏夹

Article Oncology

27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study

David L. Saltman et al.

Summary: Current biomarkers for ICI treatment in aNSCLC are not optimal. DetermaIO, a novel tumor immune microenvironment classifier, is associated with ICI response and potentially has clinical utility over existing biomarkers in aNSCLC. It provides additional stratification for first line treated PD-L1 >50% patients and identifies benefit in patients with poor performance status.

CLINICAL LUNG CANCER (2023)

添加到收藏夹

Article Oncology

Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors

Mridula Krishnan et al.

Summary: Clinical trials for immune checkpoint inhibitors (ICI) have mainly focused on patients with good performance status. However, this study found that ICI treatment in patients with poor performance status had worse outcomes, with lower overall survival and response rates. Further prospective trials are needed to define the role and effectiveness of ICI in patients with poor performance status.

JCO ONCOLOGY PRACTICE (2022)

添加到收藏夹

Review Oncology

Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma

Zeynep B. Zengin et al.

Summary: The management of urothelial carcinoma has made rapid advancements in recent years, particularly in the development of targeted therapies. The fibroblast growth factor receptor (FGFR) family has emerged as an important target, with multiple FGFR-directed therapies being developed and tested in UC and other FGFR-mutated solid tumors.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

添加到收藏夹

Article Oncology

Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

Harsha Ranganath et al.

Summary: This study evaluated the association between a 27-gene IO assay and the efficacy of ICI therapy in advanced-stage NSCLC patients, finding that the IO score was significantly associated with response and progression-free survival.

BMC CANCER (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

Robert S. Seitz et al.

Summary: This study evaluated the clinical utility of the IO Score in bladder cancer and found a strong correlation between IO Score and inflammatory gene expression. Patients with positive IO Score showed significant improvement in overall survival in the cohort treated with ICI. The significance of IO Score remained when combined with other clinical factors and biomarkers. These results suggest that IO Score may serve as a promising biomarker for ICI clinical benefit across different tumor types.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Oncology

FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

Elaine Chang et al.

Summary: Enfortumab vedotin-ejfv has been granted accelerated approval by the FDA for the treatment of locally advanced or metastatic urothelial cancer. The drug showed certain efficacy in clinical trials but also comes with a high rate of adverse reactions. This approval is subject to further verification and description of clinical benefits in confirmatory trials.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

Sebastien Benzekry et al.

Summary: By studying the determinants of response to immune-checkpoint inhibition in advanced non-small cell lung cancer patients, it was found that hemoglobin levels and performance status were the strongest predictors, and neutrophil-to-lymphocyte ratio was also associated with outcome.

CANCERS (2021)

添加到收藏夹

Article Oncology

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer

Toshiaki Iwase et al.

Summary: The study confirmed a novel 27-gene immuno-oncology signature for predicting the pathologic complete response of primary triple-negative breast cancer to neoadjuvant immunotherapy. Combining this signature with PD-L1 immunohistochemistry enhanced the predictive power. Further analysis in a larger cohort is warranted.

CANCERS (2021)

添加到收藏夹

Meeting Abstract Oncology

Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial

G. Bianchini et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience

Tracy L. Rose et al.

Summary: Our study confirms that both FGFR3-altered and wild type bladder cancers show equal response to immune checkpoint blockade (ICB). Despite the lower inflammation in FGFR3-altered tumors, they exhibit similar T cell receptor diversity as non-altered tumors. The balance of CD8 T cell gene expression signature to immune suppressive features plays a crucial role in determining the response to ICB.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles et al.

Summary: The study examined the outcomes of using pembrolizumab alone or combined with chemotherapy as first-line treatment for advanced urothelial carcinoma, and found that the addition of pembrolizumab to platinum-based chemotherapy did not significantly improve efficacy. Safety was assessed and the study concluded that this combination treatment should not be widely adopted for this type of cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study

Andrea Necchi et al.

Summary: The study analyzed the role of FGFR3 alterations in MIBC patients treated within the PURE-01 trial, finding no robust association between FGFR3 activity and gene alterations with pathological response, suggesting that patients with FGFR3-altered tumors should not be excluded from neoadjuvant immunotherapy trials.

EUROPEAN UROLOGY ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies

Tyler J. Nielsen et al.

Summary: ICI therapies can improve outcomes for solid tumor patients, with a developed algorithm capturing the immunological state of the TME showing high concordance with a 101-gene model. The algorithm can predict patient response to immunotherapy, offering incremental predictive value over current biomarkers in clinic.

HELIYON (2021)

添加到收藏夹

Article Oncology

Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab

David L. Saltman et al.

Summary: A case of simultaneous lung and pancreatic tumors responded significantly to single-agent immunotherapy and radiation therapy. Molecular analysis revealed shared key mutations in both tumors, indicating a common clonal origin. Strong immuno-oncology scores in both tumors may explain the favorable response to treatment.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors

Ali Raza Khaki et al.

CANCER (2020)

添加到收藏夹

Article Oncology

Bladder Cancer. Version 3.2020

Thomas W. Flaig et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

添加到收藏夹

Article Urology & Nephrology

Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection

Peter C. Black et al.

CUAJ-Canadian Urological Association Journal (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Erdafitinib for the treatment of metastatic bladder cancer

Kamaneh Montazeri et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)

添加到收藏夹

Article Oncology

Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.

Jonathan E. Rosenberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky et al.

LANCET (2020)

添加到收藏夹

Article Oncology

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity

Adi Reches et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions

Juan Liu et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Urology & Nephrology

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer

Li Wang et al.

EUROPEAN UROLOGY (2019)

添加到收藏夹

Article Oncology

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Jonathan E. Rosenberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Y. Loriot et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Immunology

Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment

Heidi Harjunpaa et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Review Oncology

Exosomes in cancer development and clinical applications

Yu-Ling Tai et al.

CANCER SCIENCE (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Thomas Powles et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

Andrea Necchi et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Immunology

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

William C. Dougall et al.

IMMUNOLOGICAL REVIEWS (2017)

添加到收藏夹

Article Oncology

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun V. Balar et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status

Ho Won Kang et al.

ONCOLOGY LETTERS (2017)

添加到收藏夹

Article Oncology

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients

Brian Z. Ring et al.

BMC CANCER (2016)

添加到收藏夹

Article Oncology

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

Randy F. Sweis et al.

CANCER IMMUNOLOGY RESEARCH (2016)

添加到收藏夹

Correction Oncology

Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)

Hans von der Maase et al.

ANNALS OF ONCOLOGY (2011)

添加到收藏夹

Article Pharmacology & Pharmacy

CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials

Kenneth F. Schulz et al.

JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2010)

添加到收藏夹

Article Oncology

Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

H von der Maase et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.